HC Wainwright Reaffirms Neutral Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

HC Wainwright reiterated their neutral rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $8.60 price objective on the stock, down from their previous price objective of $11.00.

A number of other brokerages have also issued reports on YMAB. Jones Trading reiterated a “hold” rating on shares of Y-mAbs Therapeutics in a report on Tuesday. Canaccord Genuity Group set a $8.60 price target on Y-mAbs Therapeutics and gave the company a “hold” rating in a report on Tuesday. Truist Financial set a $8.60 price target on Y-mAbs Therapeutics in a report on Tuesday. Bank of America downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research note on Tuesday, April 22nd. Finally, Oppenheimer downgraded shares of Y-mAbs Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $11.16.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ:YMAB opened at $8.52 on Wednesday. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11. The business has a 50 day simple moving average of $4.79 and a two-hundred day simple moving average of $4.92. The firm has a market capitalization of $385.82 million, a PE ratio of -13.31 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. Equities research analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. KLP Kapitalforvaltning AS acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth $46,000. JPMorgan Chase & Co. increased its position in shares of Y-mAbs Therapeutics by 221.9% during the fourth quarter. JPMorgan Chase & Co. now owns 97,660 shares of the company’s stock worth $765,000 after purchasing an additional 67,325 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock worth $6,440,000 after purchasing an additional 8,820 shares in the last quarter. ExodusPoint Capital Management LP acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth $253,000. Finally, Wells Fargo & Company MN increased its position in shares of Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after purchasing an additional 6,131 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.